Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload

Table 3

Overview of the analyzed study groups (0–4), the number of myelodysplastic patients, gender ratio, and the age of analyzed patients and controls.

Group	Number of patients (male/female)	Age range	Diagnoses
0	23 (10/13)	25–57	Healthy donors
1	14 (10/4)	52–91	RA, RA-5q, RARS
2	29 (15/14)	28–90	RCMD, RCMD-RS, RCMD-5q, RCMD with reactive monocytes
3	9 (4/5)	36–85	RAEB-1, MDS/MPS, MDS/MPS with 5q deletion, MDS-RAEB-1 + SC-NHL
4	9 (5/4)	55–80	RAEB-2, RAEB-T, AML M2

Refractory anemia (RA), MDS with isolated del(5q) (RA-5q), refractory anemia with ringed sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD), RCMD with ringed sideroblasts (RCMD-RS), RCMD with 5q deletion (RCMD-5q), RCMD with reactive monocytes, RA with an excess of blasts-1 (RAEB-1), RA with an excess of blasts-2 (RAEB-2), RA with an excess of blasts in transformation (RAEB-T), myelodysplastic/myeloproliferative syndromes (MDS/MPS), MDS/MPS with 5q deletion, acute myeloid leukemia (AML M2), and MDS-RAEB-1 plus SC-non-Hodgkin lymphoma.